JASPER THERAPEUTICS, INC.

Analyst Reco. Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
20.92 ^USD	+0.77%		-8.12%	+165.15%

05-13	Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	MT
05-07	Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	05-06	MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	04-03	MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	03-28	MT
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	03-18	MT
Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target	23-08-11	MT
EF Hutton Assumes Jasper Therapeutics at Buy With $6.85 Price Target	23-05-25	MT
EF Hutton Raises Price Target on Jasper Therapeutics to $6.85 From $4, Maintains Buy Rating	23-02-16	MT
Credit Suisse Lowers Jasper Therapeutics' PT to $3 From $7 After Announcing Pipeline Reprioritization, Keeps Outperform Rating	23-01-11	MT
Oppenheimer Adjusts Jasper Therapeutics Price Target to $8 From $21, Maintains Outperform Rating	22-11-14	MT
EF Hutton Starts Jasper Therapeutics at Buy With $4 Price Target	22-11-01	MT
Credit Suisse Lowers Jasper Therapeutics' Price Target to $8 from $9 on Moderately Tempered Peak Market Share Assumption, Keeps Outperform Rating	22-07-13	MT
Cantor Fitzgerald Starts Jasper Therapeutics at Overweight With $10 Price Target	22-02-28	MT
Credit Suisse Trims Jasper Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating	22-02-25	MT
Credit Suisse Starts Jasper Therapeutics at Outperform with $15 Price Target	21-11-08	MT
JASPER THERAPEUTICS : William Blair Initiates Jasper Therapeutics at Outperform Rating	21-10-21	MT
JASPER THERAPEUTICS : BMO Initiates Jasper Therapeutics at Outperform Rating With $19 Price Target	21-10-20	MT
Jasper Therapeutics : Shares Soar Midday After Initiated by Oppenheimer With Outperform Rating, $21 Price Target	21-10-13	MT
JASPER THERAPEUTICS : Oppenheimer Starts Jasper Therapeutics at Outperform with $21 Price Target	21-10-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW